# Self-assembled, Ellipsoidal Polymeric Nanoparticles for Intracellular Delivery of Therapeutics

**Journal:** *Journal of Biomedical Materials Research: Part A*

**Manuscript ID:** JBMR-A-17-0801.R2

**Wiley - Manuscript type:** Original Article

**Date Submitted by the Author:** 17-Feb-2018

**Complete List of Authors:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desai, Prachi</td>
<td>Texas A&amp;M University, Biomedical Engineering</td>
</tr>
<tr>
<td>Venkataramanan, Anjana</td>
<td>Texas A&amp;M University, Biomedical Engineering</td>
</tr>
<tr>
<td>Schneider, Rebecca</td>
<td>Cornell University Sibley School of Mechanical and Aerospace Engineering, Mechanical Engineering</td>
</tr>
<tr>
<td>Jaiswal, Manish</td>
<td>Texas A&amp;M University, Department of Biomedical Engineering</td>
</tr>
<tr>
<td>Carrow, James</td>
<td>Texas A&amp;M University, Biomedical Engineering</td>
</tr>
<tr>
<td>Purwada, Alberto</td>
<td>Cornell University Sibley School of Mechanical and Aerospace Engineering, Mechanical Engineering</td>
</tr>
<tr>
<td>Singh, Ankur</td>
<td>Cornell University Sibley School of Mechanical and Aerospace Engineering, Mechanical Engineering</td>
</tr>
<tr>
<td>Gaharwar, Akhilesh</td>
<td>Texas A&amp;M University, Biomedical Engineering</td>
</tr>
</tbody>
</table>

**Keywords:** Nanoparticles, therapeutic delivery, co-polymer, poly(glycerol sebacate), poly(ethylene glycol)
Self-assembled, Ellipsoidal Polymeric Nanoparticles for Intracellular Delivery of Therapeutics

Prachi Desai¹, Anjana Venkataramanan¹, Rebecca Schneider²,³, Manish K. Jaiswal¹, James K. Carrow¹, Alberto Purwada²,⁴, Ankur Singh²,⁴,* and Akhilesh K. Gaharwar¹,⁵,⁶,*

¹Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843 (USA)

²Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY 14853 (USA)

³Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853

⁴Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853 (USA)

⁵Department of Materials Science and Engineering, Texas A&M University, College Station, TX 77843 (USA)

⁶Center for Remote Health Technologies and Systems, Texas A&M University, College Station, TX 77843 (USA)

*Corresponding authors: gaharwar@tamu.edu (A.K.G); as2833@cornell.edu (A.S)

Keywords: Shape-specific nanoparticles, drug delivery, therapeutic delivery, bovine serum albumin.
Abstract

Nanoparticle shape has emerged as a key regulator of nanoparticle transport across physiological barriers, intracellular uptake and biodistribution. We report a facile approach to synthesize ellipsoidal nanoparticles via self-assembly of poly(glycerol sebacate)-co-poly(ethylene glycol) (PGS-co-PEG). The PGS-PEG nanoparticle system is highly tunable, and the semi-axis length of the nanoparticles can be modulated by changing PGS-PEG molar ratio and incorporating therapeutics. As both PGS and PEG are highly biocompatible, the PGS-co-PEG nanoparticles show high hemo-, immuno- and cyto- compatibility. Our data suggest that PGS-co-PEG nanoparticles have the potential for use in a wide range of biomedical applications including regenerative medicine, stem cell engineering, immune modulation and cancer therapeutics.
1. Introduction

Nanoengineered particles have been extensively investigated for delivery of therapeutics to cells and tissues for regenerative medicine, stem cell engineering, immune modulation, and cancer therapeutics.\(^1\)\(^-\)\(^4\) By modulating the physiochemical characteristics of nanoparticles, therapeutic efficacy, cellular internalization, biodistribution and \textit{in vivo} retention can be customized.\(^5\)\(^-\)\(^9\) For example, the size of these nanoparticles regulates their own uptake by the healthy (stem cells) or diseased cells (such as tumors or immune cells).\(^10\)\(^-\)\(^14\) Smaller nanoparticles (~25 nm) are preferentially transported through the lymphatics drainage system to draining lymph nodes compared to larger (~100 nm) nanoparticles.\(^15\) Smaller spherical nanoparticles are effective in delivering cargo within the cellular structures as they are readily endocytosed by cells compared to larger size nanoparticles. Whereas, for extracellular delivery and prolonged retention of therapeutics, larger sized nanoparticles have been shown to higher efficacy compared to smaller size nanoparticles.\(^5\)\(^-\)\(^8\),\(^10\)

Recently, along with the size, the shape of the nanoparticles has also emerged as a key regulator of intracellular delivery and therapeutic transport efficacy across physiological barriers.\(^16\)\(^-\)\(^19\) In addition, non-spherical nanoparticles have been shown to respond differently to endocytosis, intracellular retention, and \textit{in vivo} circulation time. For example, elongated nanoparticles show a superior pharmacokinetics profile and reduced non-specific cellular uptake compared to spherical nanoparticles.\(^18\),\(^20\),\(^21\) In addition, non-spherical nanoparticles have shown to respond differently to endocytosis, intracellular retention, and \textit{in vivo} circulation time. For example, elongated nanoparticles showed a superior pharmacokinetics profile and reduced non-specific cellular uptake compared to spherical nanoparticles.\(^22\) Thus, there is extensive interest in investigating the potential of non-spherical nanoparticles for therapeutic delivery.
Non-spherical nanoparticles, such as nanorods and nanodiscs, are effectively taken up by cells compared to their spherical counterpart. The exact mechanism responsible for preferential internalization of non-spherical particles compared to spherical particles is not well understood. However, increasing the surface area of rod- and disc-shaped nanoparticles as compared to spherical nanoparticles is believed to play an important role during cellular internalization. Nanoparticles with large surface-contact area results in stronger adhesion force and thus promote faster cellular uptake, compared to particles with small surface-contact area. Internalization of nanoparticles is attributed to complex interplay between the surface area in contact with the cell membranes and strain energy required for membrane deformation.

The majority of recent studies in this area have focused on non-spherical shapes such as rods and discs, however, little information exists on the role of ellipsoidal-shaped nanoparticles. Similar to rod-shaped nanoparticles, ellipsoidal nanoparticles also have higher surface-to-volume ratio compared to spherical nanoparticles. Due to absence of any sharp edges in ellipsoidal nanoparticles, surface strain required by cell membrane will be lower compared to rod-shaped nanoparticles. Accordingly, ellipsoidal nanoparticles for therapeutic delivery need further study. However, due to the lack of suitable polymers, it is difficult to fabricate ellipsoidal nanoparticles using conventional techniques such as self-assembly, flash nanoprecipitation and microfluidics-based preparation.

Here, we report synthesis of self-assembled ellipsoidal nanoparticles from copolymer consisting of poly(glycerol sebacate) (PGS) and poly(ethylene glycol) (PEG). PGS is biocompatible elastomeric polyester extensively investigated for soft tissue replacement and
regeneration. The degradation products of PGS, glycerol and sebacic acid are endogenous constituents and thus readily metabolize under physiological conditions. Due to the elastomeric properties and biocompatibility, PGS-based scaffolds have been investigated for cartilage regeneration, cardiac patches, bone scaffolds, and nerve conduits. Despite these advantages, to our knowledge ellipsoidal-shaped nanoparticles of PGS or copolymers of PGS have not been developed.

Earlier studies have highlighted the role of surface properties in controlling cellular internalization and therapeutic efficacy. Due to high surface energy of nanoparticle surface, proteins from biological media form protein corona that dictate cellular fate of nanoparticles. PEGylation of polymeric particles results in limited non-specific physical interactions and enhances nanoparticle stability. It is our expectation, that PEGylation of PGS can improve hydrophilicity, increases stability in serum, and prolong circulation. We synthesized PGS-co-PEG copolymer with different PGS:PEG molar ratio. Nanoparticles from PGS-co-PEG polymers will be synthesized via the nanoprecipitation method. PEGylation of PGS, results in formation of a core-shell nanoparticles with PGS core and PEG shell. We will investigate the hemo-, immune- and cyto- compatibility of PGS-PEG nanoparticles. Our report introduces a new family of ellipsoidal PGS-PEG nanoparticles for intercellular delivery and can be used to deliver a range of biomolecules for biomedical applications.
2. Experimental

Synthesis of copolymer: PGS-co-PEG polymers were synthesized by two-step polycondensation reaction with two different molar ratios of PEG segment (20 and 40) within the copolymer system using previously reported method. The first step involved the polycondensation of sebacic acid (20.22 gm) and poly (ethylene glycol) (20 or 40 gm) in 250mL three neck flask under stirring conditions. PEG was dried in vacuum chamber at 90°C before its use. The reaction was carried out further at 130°C under the flow of argon for 2h and under vacuum of 50mTorr for another 24h. In the second step a specific amount of glycerol (7.368 gm) was added, mixed thoroughly under the flow of argon and the reaction was carried out at 130°C under reduced pressure of 50mTorr for another 48h. Gel permeation chromatography (GPC, Waters, Milford, MA) was used to determine the molecular weight of copolymers using tetrahydrofuran (THF) as solvent. The overall diol to dicarboxylic acid molar ratio was kept constant. Two molar ratios of PEG to glycerol (20/80, and 40/60) were used to develop PGS-co-PEG polymers with different degrees of PEG segments within the resulting copolymer system. A close control over the condensation reaction resulted in narrow polydispersity index (PDI) for PGS-20PEG (M<sub>w</sub>~4998Da, PDI=1.48) and PGS-40PEG (M<sub>w</sub>~4037 Da, PDI=1.42).

Synthesis of nanoparticle: Nanoprecipitation method is extensively used to synthesize polymeric nanoparticles and to entrap hydrophilic drugs or proteins. Here, we have prepared PGS-co-PEG nanoparticles via the nanoprecipitation method (Fig 1a). Briefly, 5% (w/v) of the polymer was dissolved in DMSO and was slowly added drop wise to an aqueous phase to obtain self-assembled nanoparticles. The resulting solution was homogenized using a bath sonicator. Finally, the nanoparticles were collected at 17,000 rpm (20 minutes) using Beckman Optima™ MAX-XP tabletop ultracentrifuge fitted with TLA-55 Rotor and washed...
thrice. Later precipitated nanoparticle was suspended in 10mL PBS to obtain nanoparticle solution (5 mg/mL).

**Therapeutic Encapsulation:** Fluorescein isothiocyanate-labeled bovine serum albumin (FITC-BSA) was encapsulated within PGS-co-PEG nanoparticles during nanoprecipitation method. 0.5% of FITC-BSA was added to aqueous phase prior to addition of 5% (w/v) of the polymer dissolved in DMSO. During nanoparticle formation, FITC-BSA was entrapped within the nanoparticles. The amount of FITC-BSA remaining in supernatant after nanoparticle formation was determined using UV/Vis spectroscopy (n=3). Encapsulation efficiency (EE%) was determined by Eq. 1:

$$EE\ (%) = \frac{FITC-BSA\ (initial) - FITC-BSA\ (supernatant)}{FITC-BSA\ (initial)} \times 100\%$$  

Eq. 1

FITC-BSA (initial) = total amount of FITC-BSA added initially; and FITC-BSA (supernatant) = amount of FITC-BSA in the supernatant measured by quantitative UV/Vis spectroscopy.

**Physicochemical characterization of nanoparticles:** The mean particle size (hydrodynamic diameter), and electrophoretic mobility of PGS-co-PEG nanoparticles were determined using dynamic light scattering (DLS) (Malvern Instrument, UK) (n=3). The electrophoretic mobility of the co-polymers was also measured using DLS (n=3). The stability of nanoparticles under physiological conditions (in PBS and T=37°C) was monitored for three weeks. The morphological characterization of the nanoparticles was performed using JEOL JEM-2010 transmission electron microscopy (TEM) by loading nanoparticle suspension on lacey carbon grid. The sizes of the nanoparticles were quantified using ImageJ (NIH) by counting >250 particles from TEM images to determine length and width of the nanoparticles.
Cellular characterization of PGS-co-PEG nanoparticles: Preosteoblast cell lines (NIH MC3T3 E1-4, ATCC, USA) were used to determine the cytotoxicity of nanoparticles (n=5). Cells were seeded in a 48-well flat-bottomed plate at a density of $1.5 \times 10^4$ cells/well in normal growth media (Alpha MEM, supplemented with 10% FBS and 1% penicillin/streptomycin (100 U/100 µg/ml); Life Technologies, USA) and were allowed to adhere for 1 day. After 1 day, cells were treated with PGS-co-PEG at different concentrations (0.15, 0.3, 0.6, 1.25, 2.5, 5, 10 mg/mL). After incubating for 3 h and 24 h, the cells were washed with PBS (2X) and fixed with glutaraldehyde solution (2%) for 10-15 minutes. The fixed cells were stained with rhodamine-labeled phalloidin (R415, Life Technology, USA) and counter stained with 4’6-diamidino-2-phenylindole dilactate (DAPI). The cells were imaged using fluorescence microscope (TE a2000-S, Nikon, USA). Nanoparticles cytotoxicity was determined using the MTS assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) according to the manufacturer’s protocol.

Hemocompatibility of nanoparticles: The hemolytic ability of our nanoparticles was investigated using a previously reported method using fresh bovine blood obtained from Texas A&M College of Veterinary Medicine & Biomedical Sciences, College Station, TX (n=3). Briefly, Red blood cells (RBCs) were separated from whole blood by centrifugation (2800rpm, 15 minutes, 5 cycles). The purified RBCs were diluted with PBS to obtain working solution. Nanoparticles with varying concentration ($A_{NP}$) was added to RBC solution (1 mL) or whole blood (1 mL) and incubated for 3 h at 37°C (n=5). RBCs incubated with water ($A_{W}$) were used as positive control and RBCs incubated with PBS alone ($A_{PBS}$) was used as negative control. After the incubation time, the solution was centrifuged at 2000g for 6 minutes and supernatant (10 µl) was added to Drabkin’s reagent (100 µl) for quantitative calorimetric determination of hemoglobin concentration. The absorbance was read at 540 nm
using a microplate reader (Infinite M200 PRO, TECAN). Hemolysis was determined by absorbance using equation: Hemolysis (%) = ((A_{NP} – A_{PBS}) / (A_{W} – A_{PBS})) * 100

**Cellular internalization:** To investigate the endocytosis pathway, we looked into three different pathways namely micropinocytosis, calveolae mediated endocytosis and clathrin mediated endocytosis pathways (n=3). We investigate three different endocytosis pathways – i.e., (i) micropinocytosis, (ii) calveolae-mediated and (iii) clathrin-mediated – using the inhibitor drugs Wortmannin (400 nM), Nystatin (10 µM) and Chlorpromazine (35 µM) to block the respective pathways. First, cells were treated with these inhibitory drug at 37 °C for 30 mins. Then, cells are subjected to PGS-40PEG nanoparticles for 3 hours. After 3 hours of incubation, the cells were washed thoroughly with PBS and they were trypsinized to perform flow cytometry using BD Accuri™ C6 Cytometer - BD Biosciences. The cellular uptake was investigated using two different cell lines pre-osteoblasts (NIH MC3T3 E1-4, ATCC, USA) and endothelial cells (HUVEC, C2519A, Lonza Inc) lines.

**Immunocompatibility of nanoparticles:** Macrophage activation studies were performed by seeding 20,000 RAW 264.7 murine macrophage cell line (ATCC) in a 24-well plate (n=3). Following 24 h of incubation, nanoparticles were reconstituted in PBS and introduced to the cells at two different doses: 10 and 100 µg/mL. Analysis on macrophage activation was carried out after 48 h of incubation using flow cytometry with antibodies (eBioscience) targeted against two macrophage activation cell surface markers: CD80 and CD86.

**Statistical analysis:** The data was presented as mean ± standard deviation (n=3-5). Statistical analysis was performed using a one-way analysis of variance (ANOVA) with Turkey’s post hoc test for pairwise comparison. Statistical significance is designated with *via* an asterisk *p<0.05.
3. Results and discussion

3.1 Synthesis and Characterization of Ellipsoidal Nanoparticles

Nanoparticles from PGS-co-PEG polymers were synthesized via the nanoprecipitation method (Fig 1a). Briefly, copolymer was dissolved in DMSO and added to phosphate buffer saline (PBS) in a drop-wise manner to obtain self-assembled nanoparticles. This technique was based on dissolving the polymer in a water-miscible solvent followed by drop wise addition to an excess volume of aqueous phase with continual stirring. The nanoparticles were formed and precipitated during the solvent evaporation.

We hypothesized that PGS-PEG nanoparticles were formed due to the self-assembly by noncovalent interactions, which results in formation of highly organized supramolecular systems. PGS-co-PEG is an amphiphilic copolymer composed of hydrophobic PGS and hydrophilic PEG blocks with different polarities. PGS-co-PEG is completely dissolved in DMSO, but in aqueous solution they form supramolecular assemblies due to thermodynamic incompatibility between PGS and PEG blocks. It is expected that the interfacial tension between the PGS-co-PEG and the solvent mixture might result in the formation of PGS-PEG nanoparticles. When we prepared nanoparticles using PGS alone, nanoparticles were forming but started aggregating in few minutes and settle down. A plausible reason for this observation could be the hydrophobic nature of PGS. It might be possible that by modulating the molecular weight or type of solvent used, it is possible to obtain stable PGS nanoparticles. In current study, we modified PGS with PEG to increase the hydrophilicity and to provide stability to the nanoparticles.
To confirm the presence of PEG on the surface of nanoparticles, we determined the electrophoretic mobility of copolymer and nanoparticles. Both PGS-20PEG and PGS-40PEG copolymers had similar zeta potentials of -38.3±4.3 mV and -39.5±4.1 mV respectively, due to the presence of hydroxyl groups on the PGS backbone (Fig 1b). After nanoparticle formation, the zeta potentials were decreased to -21.3±3.9 mV and -23.7±3.5 mV for PGS-20PEG and PGS-40PEG, respectively. The decrease in zeta potential suggests that PGS formed the core of the nanoparticles and PEG shielded the surface of the nanoparticles to provide aqueous stability. Other studies have shown the formation of core-shell nanoparticles from copolymer systems such as poly(lactic-co-glycolic acid) (PLGA)-co-PEG, poly (d, l-lactic acid)(PLA)-co-PEG and poly(caprolacton)(PCL)-co-PEG. In addition, nanoparticles containing PEG chains on their surface have ability to provide stealth characteristics and thus can be used for systemic drug administration.

3.2 Morphology of Self-assembled Nanoparticles

To determine the morphology of self-assembled nanoparticles, transmission electron microscopy (TEM) and dynamic light scattering (DLS) were used. TEM indicated formation of elongated ellipsoidal nanoparticles from PGS-20PEG and PGS-40PEG (Fig. 1c). Quantification of images using IMAGE J (NIH) determined that PGS-20PEG nanoparticles were ~235±132 nm in length and ~48±28 nm in width and PGS-40PEG nanoparticles were ~195±110 nm in length and ~80±48 nm in width (Fig. 1c). The hydrodynamic diameter ($D_h$) of the PGS-PEG nanoparticles as determined by DLS also correlates with the data obtained from TEM. PGS-20PEG nanoparticles were $D_h$~311nm and PGS-40PEG nanoparticles were $D_h$~250nm. The increase in PEG concentration from PGS-20PEG to PGS-40PEG resulted in reduction in $D_h$ due to enhanced stability provided by PEG chains. It is expected that increase in PEG concentration, imparts higher aqueous stability to PGS-40PEG compared to PGS-
20PEG. Earlier studies have shown that by modulating the ratio between copolymer chains, it is possible to change the size and shape of nanoparticles.\textsuperscript{19,48} Our current study extends the concept of modulating the size of nanoparticle by changing co-polymer ratio towards elliptical nanoparticles. Earlier studies have shown that ellipsoidal nanoparticles are highly relevant to physical and biochemical targeting \textit{via} both systemic and site-specific deliveries.\textsuperscript{29} This is due to enhanced interfacial surface between nanoparticles and cell membrane.

From TEM and DLS studies, it is observed that we can modulate the size of elliptical nanoparticles by controlling the molar ratio between PGS and PEG. We hypothesize that the elliptical nanoparticles are formed due to block characteristics of PGS-PEG copolymer and thermodynamic incompatibility between different blocks. By modulating the ratio between PGS and PEG in the copolymer system, we can change the hydrodynamic volume fraction of PGS block with respect to the PEG block. The ratio between PGS and PEG block was also shown to dictate size of major and minor axis in the elliptical nanoparticles.

3.3 \textit{Modulating Size of Nanoparticle via Therapeutic Loading}

The size of nanoparticles has shown to play an important role in cellular internalization, tissue localization and biodistribution.\textsuperscript{49,50} The nanoprecipitation technique can be used to encapsulate a range of hydrophilic drugs and protein within nanoparticle.\textsuperscript{41,42} To evaluate the feasibility of loading a therapeutic protein within the PGS-\textit{co}-PEG nanoparticles, we selected fluorescein isothiocyanate-labeled bovine serum albumin (FITC-BSA) as a model protein. FITC-BSA was encapsulated within nanoparticles using the nanoprecipitation method. The encapsulation efficiency of these nanoparticles was 88.5\% and 91\% for PGS-20PEG and PGS-40PEG, respectively. The TEM and DLS data indicated an increase in the size of nanoparticles with an increase in protein loading (\textbf{Fig. 2a & 2b}). The addition of 25, 50, and
100 µg of FITC-BSA to PGS-20PEG increased the nanoparticle size from ~270nm to 350, 610, and 840 nm, respectively. A similar trend was observed in PGS-40PEG. These findings indicate that the size of nanoparticles can be controlled by altering the protein loading. Although large-size nanoparticles (>500 nm), cannot be used for therapeutic delivery via systemic injection, but they have potential to be incorporated within tissue engineering scaffold to provide biochemical cues. By sustained release of therapeutic within bioengineered scaffolds, cell migration and fate can be controlled. The increase in nanoparticle size due to protein loading might be attributed to localization of protein within hydrophobic domain (PGS) of nanoparticles. Similar results have been reported earlier with spherical nanoparticles.\textsuperscript{15}

3.4 Hemo- and immune-compatibility of Ellipsoidal Nanoparticles

The surface characteristics of nanoparticles determine hemo- and immune-compatibility of nanoparticles. Proteins get adsorbed on nanoparticles surface as soon as it comes in contact with biological fluids resulting in formation of protein corona. The type and amount of protein adsorbed on nanoparticles surface determine biological fate, therapeutic efficiency and toxicity of nanoparticles. The size of protein corona on PGS-PEG nanoparticles directly depend on the density and length of PEG block. It is expected that both PGS-20PEG and PGS-40PEG nanoparticles will have high hemo- and immune- compatibility due to presence of PEG on the surface. It is also expected that PGS-40PEG have higher PEG density on surface compared to PGS-20PEG nanoparticles, thus should show superior hemo- and immune- compatibility.

For systemic administration for targeted and controlled drug delivery, the mechanism of interaction of nanoparticles with blood needs to be investigated. \textit{In vivo} circulation time
directly depend on nanoparticle stability in physiological conditions.\textsuperscript{31} We investigated the
hemocompatibility of nanoparticles by determining the release of hemoglobin from red blood
cells (erythrocytes) and whole blood after exposure to PGS-PEG nanoparticles (Fig. 3a).
Purified bovine red blood cells (erythrocytes) were obtained by separating plasma proteins
from whole blood and were subjected to different concentration of nanoparticles to
investigate hemolysis ability of nanoparticles. After 24 h of incubating the nanoparticles with
red blood cells and whole blood, the supernatant was used to quantify hemolysis. PGS-
20PEG nanoparticles showed no hemolysis at a low concentration (<1 µg/mL). However, at
higher PGS-20PEG nanoparticle concentrations (5 µg/mL and 10 µg/mL), 5-10\% hemolysis
was observed. Interestingly, when the same experiment was performed with PGS-40PEG
nanoparticles, we observed less than 2% hemolysis after 3 h of incubation, even for the
highest nanoparticle concentration. While no hemolysis was observed in whole blood in both
type of nanoparticles. This might be due to presence of serum protein that might prevent any
hemolysis in whole blood. Our findings indicate that an increase in PEG concentration
increases the hemocompatibility of the nanoparticles. These results are in accordance with the
literature supporting the ability of PEGylation to enhance hemocompatibility of
nanoparticles.\textsuperscript{52,53}

Polymeric nanoparticles with long-circulating time are able to improve the clinical efficacy of
therapeutic delivery by improving pharmacokinetics, drug localization and delivery
efficacy.\textsuperscript{54,55} Nanoparticles with stealth capability are able to have long circulating time, as
they are able to maintain their structural stability without eliciting an immune response.\textsuperscript{56,57} The
stealth capability of PGS-co-PEG nanoparticles is expected to improve the
immunocompatibility of nanoparticles. We evaluated the immunocompatibility of
nanoparticles by monitoring the expression level of two co-stimulatory molecules-CD80 and
CD86 of macrophages in vitro. Incubation with increasing doses of PGS-co-PEG nanoparticles did not induce any upregulation of co-stimulatory surface markers on macrophages (Fig. 3b). In contrast, lipopolysaccharide, a potent immunostimulatory component of bacterial membrane, induced a significant increase in CD80 and CD86 surface expression on macrophages. This highlights the high immunocompatibility of PGS-co-PEG nanoparticles.

3.5 In vitro Cytocompatibility of Ellipsoidal Nanoparticles

The in vitro compatibility of PGS-co-PEG nanoparticles was investigated using preosteoblast cells (MC3T3). Cellular viability, proliferation, and morphology were evaluated at different nanoparticle concentrations. The effect of nanoparticles on cellular morphology was monitored by staining the cells for actin cytoskeleton and nucleus after 3 h and 24 h incubation (Fig. 4a). The untreated cells were flat and adherent to the substrate, with well-defined cytoskeletal structures and strong peripheral F-actin along the cell edges indicating cortical actin fibers. No significant difference was observed in cellular morphology when treated with 0.1 mg/mL and 1 mg/mL of PGS-20PEG (and PGS-40PEG) nanoparticles. However, at a higher concentration (10 mg/mL), cell shrinkage was observed due to the disruption of the actin cytoskeleton. For PGS-40PEG nanoparticles, higher concentrations of nanoparticles resulted in cells clustering with no clear sign of actin, confirming disorganization of the cytoskeleton. After 24 h, the actin cytoskeleton showed distinct morphological features caused by prolonged incubation time, which possibly obscured the actin filaments (F-actin). Earlier studies have also showed that disruption of cytoskeleton indicates potential toxicity of nanoparticles.58,59
The quantitative cytotoxicity of these ellipsoidal nanoparticles was evaluated by monitoring mitochondrial activity, which affects cell viability and metabolic activity through MTS assay. The results showed that the metabolic activity of the cells did not change after 3 h or 24 h at lower concentrations by either of the compositions. For example, at low nanoparticle concentration (<1 mg/mL), no significant change in cellular viability was observed. However, at a higher nanoparticle concentration (>1 mg/mL), a sudden decrease in cellular viability was observed. The half maximal inhibitory concentration (IC$_{50}$) for PGS-co-PEG nanoparticles was determined by fitting the dose response curve to the experimental data. The IC$_{50}$ for PGS-20PEG and PGS-40PEG was obtained around 6.3 mg/mL after 24 h exposure. The IC$_{50}$ of PGS-20PEG and PGS-40PEG nanoparticles were similar to other types of nanoparticles such as PLGA and PLGA-co-PEG nanoparticles.$^{42,44,60,61}$

3.6 Intracellular Delivery via Nanoparticles

To further investigate cellular effects of nanoparticles, the internalization of nanoparticles on the endocytosis pathways of preosteoblast and endothelial cells was determined using flow cytometry. Specifically, three different endocytosis pathways—micropinocytosis, calveolae-mediated and clathrin-mediated—were blocked using their respective inhibitor drugs wortmannin, nystatin, and chlorpromazine.$^{62-64}$ Cells were treated with empty nanoparticles, and FITC-BSA loaded PGS-20PEG nanoparticles in presence of different inhibitory drugs and compared with untreated cells. There was no significant difference between empty nanoparticles and untreated cells, this was due to absence of FITC-BSA in nanoparticles. The results showed that wortmannin and chlorpromazine showed significant suppression of cellular uptake of nanoparticles as compared to the control (no drug), indicating that micropinocytosis and clathrin-mediated endocytosis pathways are predominately responsible for nanoparticles uptake (Fig. 5). The mean fluorescence intensity of cells treated with and
without nanoparticles indicated a higher uptake of nanoparticles by preosteoblasts compared to endothelial cells.

4. Conclusions

We introduce a novel yet effective mode of synthesis of a self-assembled ellipsoidal nanoparticle system consisting of an amphiphilic copolymer derived from poly (glycerol sebacate) and poly(ethylene glycol) for therapeutic delivery. The proposed PGS-co-PEG nanoparticle system is highly tunable, and the semi-axis length of the nanoparticle can be modulated by therapeutic loading. PGS-co-PEG nanoparticles showed high cyto-, immune- and hemo- compatibility. Furthermore, the results of this study indicate that ellipsoidal nanoparticles could have a wide range of highly promising applications for proteins and peptide delivery which is claimed to be one of the rapidly developing key components in modern medical breakthrough such as regenerative medicine, stem cell engineering, immune modulation, and cancer therapeutics.

Acknowledgements

A.K.G would like to acknowledge funding support from National Institute of Health (EB026265), Texas Engineering Experiment Station, Texas A&M University Seed Grant. R.S.S was supported by the Cornell University Engineering Learning Initiative grant. A.S. would like to acknowledge funding support from Cornell University’s Sibley School of Mechanical and Aerospace Engineering and College of Engineering.
5. References


47. Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Müller R. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core...


Figure 1: Synthesis and characterization of PEG-co-PGS nanoparticles. (a) Synthesis of amphiphilic nanoparticles via nanoprecipitation method. (b) Zeta potential and electrophoretic measurements of PEG-co-PGS polymer and nanoparticles. (c) The size distribution of PGS-co-PEG nanoparticles was measured using TEM and DLS. TEM images show formation of ellipsoidal nanoparticles from PGS-20PEG and PGS-40PEG. TEM image analysis using ImageJ (NIH) was used to determine the major and minor axis dimension. The histogram represents average of minimum 100 nanoparticles. DLS data show decreased hydrodynamic diameter due to increase in PEG concentration in copolymer.

210x297mm (300 x 300 DPI)
Figure 2: Effect of protein loading on nanoparticles morphology. (a) The size of PGS-PEG nanoparticles can be modulated by loading different amount of protein (BSA). TEM images show an increase in nanoparticles size for PGS-20PEG and PGS-40PEG. (b) DLS data indicate increase in hydrodynamic diameter with protein loading. (c) Release of FITC-BSA from PGS-40PEG nanoparticles. Stability of PGS-40PEG nanoparticles was monitor using DLS during the release kinetic study.
Figure 3: Hemo- and immune- compatibility of PGS-co-PEG ellipsoidal nanoparticles. (a) The supernatants of the samples were collected after 24 h of incubation of the nanoparticles followed by centrifugation to visually observe the hemolysis activity. Bar graph represents quantitative determination of the hemolytic activity after 48 h of nanoparticle incubation with the blood. Our results indicate that PGS-20PEG nanoparticles show hemolysis at higher concentration (>1 µg/ml), but PGS-40PEG nanoparticles show hemocompatibility even at the highest nanoparticle concentration (~10 µg/ml), indicating that increase in the concentration of PEG influences the hemolytic activity. (b) PGS-20PEG and PGS-40PEG nanoparticles were tested for macrophage activation against lipopolysaccharide (Activated macrophage) using two different surface markers CD 80 and CD 86 which are known to stimulate T-cell activation and survival. Two different concentration of the nanoparticles were used in this experiment. From the figure, we observe that these nanoparticles do not activate macrophages and are immunocompatible.
Figure 4: In vitro cytocompatibility of PGS-co-PEG ellipsoidal nanoparticles. (a) Cellular evaluation of nanoparticles was determined by incubating the PGS-20PEG and PGS-40PEG nanoparticles with preosteoblast cell lines for 3 h and 24 h. Internalization of FITC-BSA loaded nanoparticles (green) was observed. Cell cytoskeleton was stained for actin filaments (red) and nucleus (blue). At higher nanoparticles concentration, disorganization of cytoskeleton was observed indicating toxicity. (b) The half maximal inhibitory concentration of the nanoparticles was evaluated by metabolic activity of pre-osteoblast cell in the presence of PGS-20PEG and PGS-40PEG nanoparticles using MTS after 3 and 24 h post treatment. The dotted line shows fitted dose response curve and IC$_{50}$ was obtained.
Figure 5: Cellular internalization of ellipsoidal nanoparticles and therapeutic efficacy. Internalization pathway determined by blocking cells treated with PGS-40PEG nanoparticles to different inhibitory drugs. Cellular uptake of nanoparticles by endothelial and preosteoblast cells. (b) Therapeutic efficacy of drug (Dox) loaded nanoparticle. The different Dox loading showed that Dox-loaded PGS-40PEG nanoparticles are effective compared to only Dox.

210x297mm (300 x 300 DPI)
Self-assembled ellipsoid nanoparticle from amphiphilic polymer are developed for therapeutic delivery. The nanoparticles showed high cyto-, immuno- and blood- compatibility. Enhanced therapeutic efficacy is observed with drug loaded nanoparticles compared to free drug.